ERBB2 and breast cancer: Then, in breast cancer, high GCS expression is correlated with multidrug resistance (MDR), the poor prognosis of estrogen receptor (ER)+ tumors (30), and metastatic ER+ and human epidermal growth factor receptor 2 (HER2)+ tumors (Luminal B) (91).